List of Biotech, Pharmaceutical & Life Sciences companies in Austria - 43

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

aitiologic is an Austrian precision medicine startup developing ai-powered solutions for early disease detection and targeted therapy.

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

Previously known as AOP Orphan, AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families as well as also the doctors and care professionals treating them. Needs. Science. Trust. The international healthcare group focuses on research, development and global sales of innovative treatment solutions. AOP Health believes it has a responsibility to make innovative integrated therapies and disease-management solutions available long term to as many patients as possible who suffer from rare diseases or require critical care.

APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies.A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for Covid-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.

Astridbio Technologies is a bioinformatics company that specializes in research data-management systems and bioinformatics data-analysis for genomics research.

At aTENSION, we are redefining the future of hypertension care. It is our mission to make advanced mass spectrometry diagnostics accessible to everyone. Our ALDO+ testing platform sets new standards in precision diagnosis and personalized treatments enhancing the well-being and life quality of hypertensive patients. With just one blood sample it identifies underlying causes of uncontrolled hypertension and personalizes treatment therapies. ALDO+ is transforming hypertension diagnostics with unparalleled benefits for clinicians, labs and patients, delivering high diagnostic value, operational simplicity and cost efficacy.

Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.

Austrianova encapsulates living cells in tiny cellulose beads. The beads act as a microenvironment for living cells, allowing them to be metabolically active and divide, whilst being protected from the environment both in vivo (immunoprotection) and in vitro (sheer force, freezing stress protection). Cell-in-a-Box® enables allogenic or xenogenic mammalian cells to be protected from rejection by the immune system, but their porous nature allows therapeutic bioproducts to be released and encapsulated cells to survive for long periods. Cell-in-a-Box® has many advantages e.g. 1) clinically proven safety and efficacy upon implantation of encapsulated cells in patients 2) cells can grow within the capsules in bioreactors and are thus protected from shear forces - especially useful for fragile cells such as stem cells 3) freezing and storage of encapsulated mammalian cells at -80C for more than 5 years and then revival with greater than 90% viability, thus cells can be easily transported on dry ice. Bac-in-a-Box® enables probiotic bacteria and yeast to be encapsulated to protect them from harsh environments. Bac-in-a-Box® has a number of advantages e.g. 1) it is based on a natural polymer which is digestible 2) it totally protects probiotics from low pH as found in the stomach for extended periods (hours), allowing almost 100% of ingested probiotic cells to reach and be released in the lower intestine 3) it allows freeze drying of probiotics without appreciable loss of viability so they can be easily stored and transported at room temperature. We offer cell encapsulation R&D and cGMP production for both - mammalian cells (stem cells, engineered cell lines etc) all the way from the lab to clinical trial material (Cell-in-a-Box®) and for - bacteria and yeast encapsulation for excellent long term storage at ambient temperatures as well as 5 to 7 logs better protection from acid degradation in the stomach and later release in the large intestine (Bac-in-a-Box®).

biocrates is the global leader in mass spectrometry-based quantitative metabolite analysis, with kits and assays covering over 1,000+ metabolites from more than 40 metabolite classes. Our platform combines innovative technology for sample preparation, metabolite identification, and data analysis. The use of quantitative, standardized, and quality-controlled metabolomics methods guarantees robust and reproducible results that are the cornerstones of all clinical research. From just a few microliters of sample material, we can uncover the entire phenotype of an individual and answer a host of questions about systems biology.

Biomay is a GMP manufacturer for plasmid DNA, mRNA and recombinant proteins. We are both technology focused and quality oriented. Our clients appreciate Biomay’s flexibility and reliability. From gene construction to market supply: Biomay delivers for the success of its clients.

We develop technologies for site-specific drug delivery to the Central Nervous System, in particular the brain, for effective care of high-need patients.

Kilobaser is a Biotechnology company that offers in-house DNA and RNA synthesis services with the Kilobaser DNA & RNA Synthesizer for fastest access to molecular tools, producing ready-to-use modified oligos on-demand.

Medical Devices, Small Molecules

We are a young biotech start-up located in Vienna, Austria focusing on targeted drug delivery systems to develop new immunotherapies – such as anti-viral vaccines and treatments for autoimmune diseases.

Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering a new solution where conventional therapies have fallen short.

Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries.Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.

Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this.

Innophore is a biotechnology company based in Graz, Austria, founded in 2017. It specializes in drug and enzyme discovery, primarily serving the biotech and pharmaceutical industries. As a spin-off of acib GmbH and the University of Graz, Innophore is supported by strategic investor EOSS Industries GmbH. The company focuses on developing high-value industrial and therapeutic enzymes, as well as environmentally friendly chemical production processes. Innophore employs an AI-guided platform that utilizes advanced 3D point-cloud technology to analyze protein structures, enhancing the identification and optimization of protein candidates. Its Catalophore platform improves traditional methods, enabling more effective drug repurposing and side-effect prediction. With access to high-performance supercomputing resources, Innophore can analyze extensive protein structure databases, accelerating research and development in the biotech sector. The company collaborates with a diverse team of experts and has established partnerships with leading global companies, including Merck and Henkel.

Innovacell Biotechnologie AG is an innovative biotechnology company that develops personalized cell therapies for treatment of incontinence.

Innovacell is an innovative biotechnology company that develops personalized cell therapies for treatment of incontinence.

Inte:Ligand supports scientists worldwide with innovative approaches for early drug discovery research using computer-aided design solutions. Molecular designers in the pharmaceutical, cosmetic, nutrition, animal health and agro science industries use our solutions to design and identify novel bioactive molecules. We develop the most innovative and user friendly modeling software platforms and provide expert consulting to inspire the innovative process of designing molecules, filtering ideas, and de-risking candidates. Our off the shelf computer-aided design tools include LigandScout, ilib:Diverse, IL PharmDB and the IL Expert KNIME Extensions as well as validated 3D-chemical pharmacophore models for toxicity prediction and precomputed libraries for virtual screening. We provide all of the tools and knowledge you need for successful early drug discovery projects including training and validated workflows to help scientists design and identify bioactive molecules efficiently and productively.

invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the biotechnology value chain, with in-house expertise in R&D, clinical development, CMC, IP, scouting and more. All of our approaches are designed with a single goal: To transform patients' lives, so that cancer doesn’t.

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI).

---If you are interested in working with us, please send an application to jobs@medphoton.at We look forward to hearing from you!--- Medphoton is the developer of ImagingRing™ technology, the world´s most innovative and patented solution intended for precise image guided radiotherapy (IGRT). The slim-line system attaches to a robotic patient couch and allows remote imaging of tumours and organs at risk, in both 3D and real time, while the the patient is positioned at the treatment isocenter. Furthermore, the dual energy acquistions and cutting edge spatial resolution provide enhanced soft tissue characterization. In addition, Medphoton´s software provides: - Adaptive Radiotherapy (ART) with online and offline corrections for accurate beam delivery - A multiple client server for Oncology Information Systems (OIS), whereby the image data can be stored, reviewed and archived during radiation therapy, along with treatment plans and dose distributions.

Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Each screening project is customized to the specific needs of our clients and we perturb cells with CRISPR KO, CRISPR interference or CRISPR activation coupled to high-content read-outs such as fitness, FACS and single-cell transcriptomics. Notably, we offer single-cell CRISPR screens (CROP-Seq) in cancer cells and primary immune cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Nabriva is a commercial-stage biopharmaceutical company with locations in the United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters.

Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodeler) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer. This “Active Checkpoint Control Immunotherapy” activates all four naturally available tumour killing mechanisms of the immune system without triggering side effects. The company’s lead candidate OQR100 (TYG100), co-developed with TYG Oncology Ltd. and CR-UK, targets pancreatic cancer and induces neutralizing antibodies against gastrin, a major growth factor for pancreatic- and other forms of gastric cancer. OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral (IgG and IgA) and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both lead candidates, which have achieved in vivo Proof of Concept in non-human primates, as well as the S-TIR™ technology platform are now available for out-licensing.

QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute of Molecular Pathology (“IMP”), both located in Vienna, Austria.

Let's write the future of DNA. Ribbon Biolabs is a biotech start-up working on developing the next technological wave of error-proof DNA synthesis. With its approach, company is developing a cost-efficient platform to produce long and complex DNA molecules, thereby enabling a new generation of biopharmaceutical processes and other synthetic biology products. Our international and highly motivated team located in Vienna is constantly looking for new talents who can join this exciting ride and take Ribbon Biolabs to the next level.

Scantox is a preclinical GLP-accredited CRO, specialized in providing services within the drug development process Discovery, Genetic Toxicology, Regulatory Toxicology and Pharmaceutical Development & Analytical. Based on decades of experience, we are a trusted partner for CRO services for the pharmaceutical and medical devices industries. The Scantox Group is headquartered in Ejby, Denmark, with subsidiaries in UK, Austria, Denmark and Sweden (Lund and Gothenburg). The Scantox services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. The Scantox team is passionate about the common vision to improve the health of people, and all processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™. #pharmacology #toxicology #histopathology #pathology #minipigtoxicology #neuropharmacology #genotox

Pioneering Biopharma: Single Use Support provides innovative fluid and cold chain management solutions around single-use technologies for biomanufacturers and CDMOs in the pharmaceutical industry. Our mission is to improve patient safety by providing our customers with products and services that enable our customers to manufacture and transport life-saving liquid pharmaceuticals and drug substances more safely and efficiently around the world. In doing so, we contribute to the most valuable process of all: Curing diseases & saving lives. We offer specific expertise and fast solutions in processes related to advanced cell and gene therapies (CGT), as well as commercial bulk drug substance handling and vaccine manufacturing transfers and drug productions. Our product range includes single-use bioprocess containers, single-use assemblies, protective shells (RoSS) as secondary packaging for bioprocessing single-use bags, freeze-thaw platforms, fill-drain platforms, 3D bag totes, ultra-cold storage, transport containers and more.

At TAmiRNA we drive innovation through microRNA and RNAi technology to solve unmet clinical needs. Circulating microRNAs are novel minimal-invasive biomarkers that fulfil the requirements of valuable markers. TAmiRNA excels in the identification and development of microRNA biomarkers for diagnosis and prediction of disease and treatment response with a special focus on musculoskeletal, cardiovascular and metabolic diseases. TAmiRNA is a biotech R&D company based in Vienna, Austria. ---- Privacy Policy and Imprint can be accessed by clicking "Contact us" ----

At Technoclone we see innovation as our duty to help overcome new complexity in the diagnostics of hematological and cardio-vascular disorders. Today more than ever. Technoclone is a world-leading producer of diagnostics tests; equipment’s and research products in the area of blood clotting and offers one of the most complete product portfolios on the market. The Ceveron 100 series is the first fully automated coagulation analyzer series for clotting, chromogenic, turbidimetric assays, thrombin generation and quenching technology (as for FXIII & ADAMTS13 activity). With the development of the new high power LED quenching module the Ceveron s100 is a milestone in speciality haemostasis diagnostics. Technoclone, on the forefront of diagnostic challenges of tomorrow.

ThioMatrix is specialised on the development of non-invasive drug delivery systems utilizing its core technologies: the Thiomer Technology and SEDDS Technology. Due to the great potential of these technologies the efficacy of non-invasively delivered: -therapeutic peptides -peptidomimetics -nucleic acids such as oligonucleotides, plasmid DNA and siRNA -class III drugs according to the biopharmaceutical classification system (BCS) -drugs being substrate of efflux pumps such as anticancer drugs can be tremendously improved. A wide network of partnerships and collaborations with hospitals, veterinary institutions, CROs and universities has been established to conduct preclinical through to clinical development of our delivery products. This network coupled to our technologies and expertise gives us the edge to reduce the time to market to develop the optimal delivery systems for your therapeutic candidates. To learn more about our drug delivery technologies, please visit the technology section where you will also find the results of various in vivo studies demonstrating the advantages of our novel drug delivery products.

No idea what they do

VALANX Biotech is a biotechnology company based in Graz, Austria, founded in 2017 as a spin-off from Graz University of Technology. The company specializes in site-specific protein conjugation, focusing on advancing biologics development through synthetic biology and genetic code expansion. VALANX operates additional lab facilities at the Vienna Biocenter. The company offers a patented protein conjugation platform that allows precise control over conjugation sites and modifications on target proteins. This technology incorporates non-natural amino acids, enabling the development of protein-drug conjugates, diagnostics, and biocatalysis products. VALANX aims to create biologics for therapeutic and diagnostic applications, particularly in cancer drug targeting, with the capability of up to 10 selectable conjugation sites per protein. The company collaborates with partners to enhance reproducibility and cost efficiency in conjugate development and has raised $2.56 million in funding.

VelaLabs - founded 2006 - is a GLP and GMP-certified and G(C)LP compliant contract laboratory focusing on analytical and quality services of biopharmaceutical products supporting BIOTECH and PHARMA companies in the clinical development of biosimilars, biologics and ATMPs. By the acquisition of LABH in 2019 and building a clean room in 2020, VelaLabs also offers all types of microbiological services. Together with its strong team, the VelaLabs Management aims to successfully realize its vision of being a trusted partner for our customers along the process of medication development.

ViennaLab Diagnostics is a medical diagnostics company that develops and manufactures user-friendly in-vitro diagnostic products for human genetic testing, specializing in assays for detecting genetic variants associated with genetic disorders and pharmacogenetics.

Digitize the patient journey with XUND's API-first medical devices and guide your patients to the right decision. From prevention to diagnosis and monitoring.

YGION Biomedical GmbH is an Austrian biotechnology company dedicated to developing individualized cancer immunotherapy. The company applies groundbreaking technology to create personalized neoantigen-based cancer vaccines, with a focus on maximizing effectiveness and minimizing side effects.